FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington,	D.C.	20549	

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SHALLCROSS STEVEN A					2. Issuer Name and Ticker or Trading Symbol Synthetic Biologics, Inc. [SYN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
-				[3. Date of Earliest Transaction (Month/Day/Year)								X X	Director Officer (giv	ve title		10% Owi			
(Last) (First) (Middle) C/O SYNTHETIC BIOLOGICS, INC.						12/06/2018								below) CEO and CF		below)				
9605 MEDICAL CENTER DRIVE, # 270				-								6 1 1								
——————————————————————————————————————				— l'	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	LLE I	MD	20850									X	Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	((State)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			. Transac Date Month/Da		Executio r) any	2A. Deemed Execution Date, any (Month/Day/Yea		Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4.			and 5) Securities Beneficially Following Re		6. Own Form: I or Indi (Instr. 4	Direct (D) III	7. Nature of ndirect Beneficial Dwnership			
							С	Code	/	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				nstr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercis	sable		xpiration ate	Title	Amount or Number of Shares		Reporte Transac (Instr. 4	tion(s)				
Stock Options	\$0.6895	12/06/2018		A		200,000 ⁽¹⁾		12/06	5/2018 ⁽¹⁾	1	2/06/2025	Common Stock	200,000	\$0	200,	000	D			

Explanation of Responses:

/s/ Steven A. Shallcross 12/07/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} These options will vest monthly on a pro rata basis over 36 consecutive months.